Axon Enterprise (NASDAQ:AXON) PT Raised to $360.00

Axon Enterprise (NASDAQ:AXON) had its price objective boosted by equities research analysts at Robert W. Baird from $355.00 to $360.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price objective would suggest a potential upside of 2.28% from the stock’s current price.

A number of other analysts also recently issued reports on AXON. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research report on Wednesday, April 24th. JMP Securities restated a “market outperform” rating and set a $375.00 target price on shares of Axon Enterprise in a report on Tuesday, May 7th. Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target for the company. Bank of America initiated coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective on the stock. Finally, JPMorgan Chase & Co. increased their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $347.15.

Axon Enterprise Trading Up 19.3 %

NASDAQ:AXON traded up $56.99 during trading hours on Wednesday, reaching $351.99. 1,685,891 shares of the company were exchanged, compared to its average volume of 505,991. The firm has a market cap of $26.56 billion, a price-to-earnings ratio of 107.32, a PEG ratio of 6.59 and a beta of 0.95. The stock has a 50 day simple moving average of $296.14 and a 200 day simple moving average of $294.62. Axon Enterprise has a 52-week low of $175.59 and a 52-week high of $367.95. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The business had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. During the same period last year, the company posted $0.80 EPS. The business’s quarterly revenue was up 34.5% on a year-over-year basis. As a group, analysts predict that Axon Enterprise will post 2.35 EPS for the current year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the business’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total transaction of $279,747.96. Following the completion of the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Joshua Isner sold 44,000 shares of the stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $309.96, for a total value of $13,638,240.00. Following the completion of the transaction, the president now directly owns 275,843 shares of the company’s stock, valued at approximately $85,500,296.28. The disclosure for this sale can be found here. Over the last quarter, insiders sold 89,447 shares of company stock worth $27,684,677. Insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently made changes to their positions in AXON. ING Groep NV raised its holdings in Axon Enterprise by 9.3% during the fourth quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock worth $2,491,000 after purchasing an additional 821 shares in the last quarter. Avantax Advisory Services Inc. boosted its stake in Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 40 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Axon Enterprise during the first quarter worth about $931,000. Sumitomo Mitsui Trust Holdings Inc. raised its position in Axon Enterprise by 14.8% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock worth $53,307,000 after acquiring an additional 22,013 shares in the last quarter. Finally, Apollon Wealth Management LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at about $234,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.